What next after infliximab?

American Journal of Gastroenterology

Volumn 100, Issue 1, 2005, Pages 80-83

  Baidoo, Leonard ^b   Lichtenstein, Gary R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; CORTICOSTEROID; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PARACETAMOL; PROTEIN INFLIXIMAB ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT HUMAN INSULIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; AUTOIMMUNITY; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGENICITY; MAINTENANCE THERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG TOLERANCE; NOTE;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 13744253564     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41716.x     Document Type: Review

References (12)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359:1541-9.
2. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
3. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of re treatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9.
4. Papadakis KA, Targan SR. Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 2000; 119:1148-57.
5. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
6. Hanauer SB, Wagner CL, Mayer L, et al. Incidence and importance of antibody response to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastrol Hepatol 2004;2(7):542-53.
7. Lichtenstein GR, Olson A, Bao S, et al. Infliximab treatment does not result in an increased risk of intestinal strictures or obstruction in Crohn's disease patients. ACCENT I study results. Am J Gastroenterol 2002;97(10).
8. Lichtenstein GR, Cohen RD, Feagan BG, et al. Use of Crohn's disease medications, including infliximab, are not risk factors for the development of intestinal stricture, stenosis or obstruction-Data from the 6000-Patient TREAT Registry. Am J Gastroenterol 2004;99(10):S250.
9. Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000;355:735-40.
10. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Therap 2003;25:1700-21.
11. Sandborn WJ, Hanauer S, Loftus EV, et al. An open label study of human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004.
12. Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Adalimumab for Crohn's disease with attenuated response to infliximab. Am J Gastroenterol 2004.